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Gerald G. Krueger2
We report the use of non-invasive tape stripping to sample psoriatic lesional and non-lesional skin in 96
patients. The procedure was well tolerated with any discomfort described as mild; we did not observe any cases
of Koebner phenomena at any non-lesional tape-stripped sites. Tape-harvested epidermis was extracted for
RNA, which was profiled by semiquantitative reverse transcriptase-PCR. This analysis revealed that mRNAs for
tumor necrosis factor a, IFNg, Krt-16, CD2, IL-23A, IL-12B, and vascular endothelial growth factor are
overexpressed in the ‘‘average’’ psoriatic lesion in a majority of patients. In addition, 10 of these patients
were biopsied at lesional and non-lesional sites and the expression data compared to tape-stripping data. This
comparison shows that five of seven mRNA are more highly expressed in cells captured by tape stripping than
biopsy, suggesting that the upper aspect of a lesion contains cells very active in the disease. The tape-harvesting
data reveal that approximately 46% of lesions have at least one pathogenic mRNA within non-lesional skin
limits. Data demonstrate that tape stripping reveals mRNA markers not detected in biopsy samples and thus the
method may be a useful supplement to biopsy.
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INTRODUCTION
Psoriasis is a common inflammatory skin disorder, estimated
to affect 1–3% of the world’s population and is characterized
by lesions exhibiting erythema, induration, and scaling
(Peters et al., 2000). At the physiological and molecular
level, psoriasis is a complex disease highlighted by hyper-
proliferative keratinocytes, defective differentiation and
barrier formation, dermal and epidermal infiltration by
diverse leukocytes, and profoundly altered gene expression
(Lew et al., 2004). Much of our knowledge concerning the
pathophysiology of psoriatic skin lesions has been derived
from biopsies of lesional and non-lesional control skin (also
referred to as uninvolved skin) of a psoriatic patient. While
biopsy data have been invaluable in characterizing psoriatic
skin, the invasive nature of biopsy makes it much less
practical as a method for repetitive clinical investigation
of psoriatic lesions. Repetitive non-invasive monitoring of
this skin disease would be of considerable value if the
information obtained reflected the pathophysiological state of
the lesion.
Tape stripping or tape harvesting is a non-invasive method
that allows recovery of cells comprising and associated with
the upper epidermis (Morhenn et al., 1999; Wong et al.,
2004). Recently, it has been demonstrated that the sequential
application of four small adhesive tape strips to a normal or
inflamed skin site is sufficient to recover a skin sample whose
RNA population can be profiled by quantitative reverse
transcriptase-PCR or DNA microarray (Wong et al., 2004).
The application of this method to dermatological disease – in
concert with RNA profiling – could allow for more precise
diagnosis and facilitate the pharmacogenomic characteriza-
tion of skin diseases by allowing large amounts of informative
molecular data to be gathered; which because it can be
gathered in a non-invasive manner would otherwise be
unavailable.
Herein we describe the use of tape harvesting as a method
for routinely recovering pathologic information in messenger
RNA from the surface of psoriatic and non-lesional skin. We
show that the tape harvesting of psoriatic patients gives
relatively large quantities of total RNA and that RNA profiles
contained within the recovered RNA are consistent with the
body of biopsy data in the literature. In a subset of patients,
we directly compare biopsy and tape-stripping results. We
observe that biopsy and tape-strip RNA samples provide
largely similar but also individually unique data suggesting
ORIGINAL ARTICLE
2234 Journal of Investigative Dermatology (2006), Volume 126 & 2006 The Society for Investigative Dermatology
Received 13 January 2006; revised 20 April 2006; accepted 21 April 2006;
published online 1 June 2006
1DermTech International, La Jolla, California, USA and 2University of Utah
School of Medicine, Department of Dermatology, Salt Lake City, Utah, USA
Correspondence: Dr Nicholas R. Benson, DermTech International, 11099 N.
Torrey Pines Road, La Jolla, California 92037, USA.
E-mail nbenson@dermtechintl.com
Abbreviations: TNFa, tumor necrosis factor a; VEGF, vascular endothelial
growth factor
that tape stripping is an important addition to biopsy as a
sampling technique.
RESULTS
Recovery of RNA from lesional and non-lesional skin
In this study, we tape stripped 96 patients at one lesional site
and three non-lesional control sites. From lesions, an average
of 116719.5 ng of RNA was recovered; from the combined
three control skin sites an average of 83717.3 ng of total
RNA was isolated (median recoveries were 46.2 and 25.3 ng,
respectively). As the control sample was a pool of three
separate skin sites (described in Materials and Methods) and
the lesion samples were from a single site, it is clear that
substantially more RNA was harvested from lesional skin than
control skin.
Gene expression in lesional and non-lesional skin
Gene expression has been well characterized in lesional and
non-lesional skin by both immunohistochemistry and quanti-
tative reverse transcriptase-PCR, using incisional skin bio-
psies to procure samples (Yawalkar et al., 1998; Trepicchio
et al., 1999; Bhawan et al., 2004; Lee et al., 2004). To
determine if tape harvesting could yield data consistent with
this body of work, we assayed the samples described above
for the mRNAs listed in Table 1. These mRNAs (with the
exception of tumor necrosis factor (TNF)a) are known to be
elevated in lesional skin and characteristic of psoriatic
disease. Table 1 shows the average fold increase of the
(gene/b-actin) mRNA ratio in lesion samples relative to non-
lesional control skin. The table shows that, on average, all of
the mRNAs are significantly (95% confidence interval)
overexpressed in lesional skin. This result indicates that
RNA recovered using the tape-harvesting method yields data
qualitatively identical to biopsy-recovered RNA (Yawalkar
et al., 1998; Trepicchio et al., 1999; Bhawan et al., 2004; Lee
et al., 2004). In later sections, we confirm this observation
with analysis of a subset of patients for which we have biopsy
samples and address the observation of increased TNFa
mRNA in tape samples.
Table 1 shows that in our sample of 96 patients, lesional
skin contains, on average, elevated levels of pathogenic
mRNAs. However, inspection of individual patient data
reveals that there is heterogeneity in specific (gene/b-actin)
mRNA ratios (data not shown). To reveal this heterogeneity in
lesion gene expression we refer to the DCt value, an
experimental measure of the (gene/b-actin) mRNA ratio in a
sample (described in Materials and Methods). By comparing
individual (gene/actin) mRNA ratios (i.e. DCt values) to
average values from our 96 patients, we can classify a sample
as being ‘‘lesion-like’’ or ‘‘non-lesion-like’’. For reference,
the average lesion and non-lesion DCt data is shown in
Table S1.
By comparison of individual patient DCt values (data not
shown) to the average values shown in Table S1, we can
determine if individual lesions overexpress each of the
mRNAs shown in Table 1. We have carried out such a
comparison for all 96 patients and summarize the results in
Table 2. The table shows the number of lesion samples with
specific gene expression characteristic of non-lesional skin.
For instance, of the 95 lesion samples with quantifiable TNFa
mRNA, there were five DCt, TNF values that were character-
istic of average control skin. Similarly, of 92 lesion samples
with quantifiable CD2 mRNA, 22 samples were determined
to have DCt, CD2 values characteristic of control skin.
Furthermore, if one asks how many of the 96 lesion samples
have significant increases in all the mRNAs, we find that 52
samples have increased expression of all mRNAs (K16 is not
included in this analysis for reasons discussed later). Thus, 44
of the lesions (46%) have at least one mRNA with expression
characteristic of non-lesional skin.
Table 1. Average fold change in (gene/b-actin) mRNA ratio in lesional relative to non-lesional psoriatic skin
Average fold change1
TNFa IFNc2 CD2 Krt-16 IL-12B2 IL-23A VEGF
7 (5–7.5) 6 (1.6–20) 2.5 (1.8–2.7) 2 (1.6–2.1) 6.2 (1–63) 6.8 (3.5–9.2) 5 (4–5.3)
1The average fold change in lesional psoriatic skin relative to non-lesional control skin is calculated as described in Materials and Methods using the data in
Table S1. The 495% confidence interval is given in parenthesis below the fold change.
2These confidence intervals are large because mRNA for these markers could only be detected in two (IFN) and four (IL-12B) control skin samples.
Table 2. Identification of lesions with levels of pathological mRNA within control skin limits
Number of patients displaying a lesion with gene expression characteristic of control skin1
TNFa IFNc CD2 Krt-16 IL-12B IL-23A VEGF
5 (95) 17 (82) 22 (93) 30 (96) 22 (85) 10 (93) 3 (96)
1The number of patients presenting a lesion with mRNA expression characteristic of non-lesional skin. For example, five of 95 lesions with assayable TNFa
mRNA had a DCt, TNF 48.2 (average control DCt, TNF minus 1 SEM; Table S1; see Materials and Methods for a full explanation of how lesions were
evaluated), demonstrating that these five lesions do not overexpress TNFa mRNA; one out of the 96 samples could not be evaluated for TNFa because of low
RNA yield. The total number of lesions considered is in parentheses; some lesion samples did not have sufficient RNA to be evaluated for some markers.
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Comparison of gene expression in biopsy and tape-strip samples
In 10 of our 97 patients, we obtained 4 mm punch biopsies
from lesional and non-lesional skin directly adjacent to sites
which had been tape stripped. The biopsies were further
divided into epidermal and dermal sections and RNA
prepared from each section. Table 3 shows the comparison
of average change in gene expression in lesional relative to
control skin in biopsy and tape samples from these patients.
In this table, each sample of tape, biopsy-epidermis, and
biopsy-dermis from lesional skin is calibrated to the same
sample type from non-lesional skin. Thus, the average RNA
expression in tape-strip samples of lesions is calibrated to
average expression in tape-strip samples of non-lesional skin;
lesion epidermis-biopsy samples are calibrated to control
epidermis-biopsy samples, etc.
In comparison of the average fold expression for all 96
subjects (Table 1) with the subset of 10 tape-strip patients for
which we have biopsies (Table 3), we see that, with one
exception, all of the (mRNA/actin) mRNA ratios are increased
in the subset of 10 tape-strip lesion samples. The sole
exception is K16 mRNA, whose average expression is not
significantly overexpressed in the subset of 10 tape-strip
lesion samples (K16 mRNA is significantly overexpressed in
the larger set of 96 samples shown in Table 1). Thus,
excepting the K16 data, the 10 tape-strip group is largely
representative of the larger sample. In contrast, comparison of
gene expression in tape-strip RNA versus epidermal- and
dermal-biopsy RNA reveals some interesting differences,
described below.
Table 3 shows that the (TNFa/b-actin) mRNA ratio in our
subset of 10 tape samples of psoriatic lesions is 9-fold
elevated relative to control tape samples. In contrast, the
epidermis- and dermal-biopsy mRNA ratios are not signi-
ficantly different in lesional versus control samples. Our
subset of 10 tape-strip data are in agreement with the larger
sample set (Table 1) and our biopsy data are in agreement
with published data. Therefore, we conclude that TNF mRNA
is overexpressed in cells in the very upper epidermis of a
psoriatic lesion; presumably, these cells are diluted out by the
majority of other cells captured by a biopsy. This demon-
strates that tape stripping is a more sensitive sampling method
for assay of TNFa mRNA than is biopsy.
Similar data are revealed for IL-23A expression. Although
the average fold increase in expression in lesion versus
control is 2.7- and 3.9-fold for tape and epidermis-biopsy
samples, respectively, inspection of individual DCt data
reveals that tape-strip samples have a much higher (IL-23A/
b-actin) mRNA ratio than do epidermis-biopsy samples. The
average DCt, IL23A in lesion tape samples was 5.9, while the
average DCt, IL23A in the epidermal-biopsy fraction was 10.55
(for DCt values a lower number indicates higher expression);
this difference in DCt values corresponds to a 2
(5.9–10.55) or
25-fold higher (IL-23A/actin) mRNA ratio in tape versus
epidermal-biopsy lesion samples.
For K16 mRNA expression, we see a slight, but not
significant 1.3-fold increase in the (K16/actin) mRNA ratio in
the subset of 10 tape samples of lesional relative to control
skin (Table 3). However, epidermal- and dermal-biopsy
lesion samples show, respectively, 71- and 26-fold increases
relative to non-lesional skin. If we examine the average DCt
values for tape-strip samples (Table S1; all 96 subjects) and
epidermal-biopsy samples from control skin, we find that
Table 3. Average fold change of inflammatory mRNAs
from 10 matched tape and biopsy samples in lesional
psoriatic skin relative to control skin
Sample source and fold change in gene expression
Biopsy3
Gene Statistic1 Tape2 Epidermis Dermis
TNFa Fold change 9 0.8 0.7
95% CI (5.4–15) (0.4–1.5) (0.4–1.1)
N (10, 4) (9, 10) (9, 10)
IFN Fold change 3.1 2 1
95% CI — — —
N (7, 1) (9, 1) (9, 1)
CD2 Fold change 2.7 3.9 1.7
95% CI — (1.8–8.6) (0.9–3.3)
N (9, 1) (9, 10) (9, 10)
K16 Fold change 1.3 71 26
95% CI (0.7–2.5) (18–280) (8.5–79)
N (10, 9) (9, 10) (9, 10)
IL-12BFold change 4.64 9.4 3.1
95% CI — — —
N (8, 0) (9, 1) (8, 1)
IL-23AFold change 2.7 3.9 0.84
95% CI (0.7–11) — —
N (10, 2) (9, 1) (9, 1)
VEGF Fold change 2.8 1.6 1.2
95% CI (1.4–5.6) (0.91–2.7) (0.95–1.5)
N (10, 8) (9, 10) (9, 10)
1Calculation of fold change and 95% confidence interval (95% CI) is
described in Materials and Methods; N is the number of lesion and control
samples upon which the fold-change calculations are based and are
shown as (no. of lesion, no. of control).
2Data from the 10 tape-strip samples for which we have accompanying
biopsy samples, for fold-change calculations of IFNg and CD2 mRNAs
only one of the 10 control tape samples had detectable IFN or CD2
mRNA, thus the fold change is based on that single sample and no 95% CI
is presented.
3Data for lesion and control biopsy samples split into epidermal and dermal
fractions. Data for 10 control samples and nine lesion samples are presented.
The average fold change for IFNg, IL-12B, and IL-23A (gene/actin) mRNA
ratio in lesions is calibrated on the single control sample in which specific
mRNA could be assayed (specific mRNA could not be detected in nine
control samples), therefore, no 95% CI given for these mRNAs.
4In this subset of 10 tape-strip samples of control skin IL-12B mRNA could
not be detected, therefore in order to calculate a fold change for IL-12B
mRNA we used the average DCt, IL12B value of the four of 96 tape samples
where IL-12B mRNA could be assayed (taken from Table S1).
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tape samples have a 2(1.463.81) or 38-fold higher (K16/
actin) mRNA ratio than epidermal-biopsy samples (Table S1).
Thus in non-lesional skin, there is active K16 expression in
the very upper epidermis (revealed by tape stripping) that is
not seen in the epidermal-biopsy sample (or the dermal
sample). We also observe this high expression of K16 mRNA
in tape-strip samples from normal healthy individuals (data
not shown).
In lesion samples, the activity of K16 expression in tape,
epidermis, and dermis RNA samples is approximately equal
(Table S1). Therefore, the large changes in K16 mRNA
expression induced by psoriasis are occurring deeper in the
skin, in layers of a lesion not sampled by tape stripping.
For the remaining mRNAs, the average fold-change data in
Table 3 show that changes revealed in tape-strip lesion
samples are qualitatively mirrored by similar changes in
epidermal-biopsy lesion samples. The data in Table 3 also
show that in general the large changes in mRNA expression
are restricted to the epidermis, since the dermal sections
show few significant changes in lesional compared to control
dermis, the sole exception being K16 expression which, as
might be expected because of the acanthotic epidermis, is
increased in psoriatic dermis compared to the control dermis.
DISCUSSION
In this study, we demonstrate that mRNA can be recovered
from the surface of lesional and non-lesional skin of psoriatics
using a non-invasive tape-stripping method. Further, we have
shown this RNA can be quantitatively assayed for specific
mRNAs. This work expands the work of Wong et al. (2004)
who have generated similar data for normal skin and sodium
lauryl sulfate-inflamed skin.
In the course of tape-harvesting the superficial epidermis
from lesional and non-lesional skin of 96 subjects with
psoriasis, we observed no adverse events, including any
evidence of the Koebner phenomenon. Previously, we
reviewed the literature, reported our experience and noted
that E30% of psoriatic subjects will develop psoriasis in
areas receiving significant trauma (Eyre and Krueger, 1991).
In this review, it was noted that ‘‘deep’’ tape stripping has
been reported as inducing the ‘‘Koebner reaction.’’ The fact
that we have not seen psoriasis develop in any of the three
control sites in the 96 subjects we report here nor in the over
300 patients we have treated since (data not presented)
argues favorably for this method of sample collection as
being minimally invasive and easily tolerated.
There is mounting evidence that psoriasis is an immune-
mediated disease, where activated T cells and activated
dendritic cells are the principle effectors (Lew et al., 2004;
Lowes et al., 2005) and a hyperproliferative, poorly
differentiated epidermis is the result. The mRNAs we have
chosen to assay (Table 1) are well described in the literature
with direct involvement in the pathogenesis of psoriasis,
being markers of general inflammation, activated T cells or
hyperproliferative keratinocytes. Our gene expression data
from tape-harvested and biopsied lesions are – excepting K16
and TNFa mRNA expression – qualitatively in compete
agreement with known gene expression profiles describing
the ‘‘average’’ psoriatic lesion, data which is all based on
biopsies (Yawalkar et al., 1998; Trepicchio et al., 1999;
Bowcock et al., 2001; Oestreicher et al., 2001; Lee et al.,
2004).
In our comparison of lesion versus control skin gene
expression in tape strip, epidermal-, and dermal-biopsy RNA
samples, we have observed a general trend of higher
expression in tape and epidermis-biopsy lesion samples and
modest or no change in dermis-biopsy samples. Thus,
generally speaking tape-strip RNA and epidermal-biopsy
RNA gave equivalent results. Exceptions to these observations
were the already noted changes in TNFa and K16 mRNA
expression.
While it is well established that TNFa protein is increased
in psoriatic lesions, increases in TNFa mRNA have not been
demonstrated (Zhou et al., 2003; Johansen et al., 2006). The
lack of increased TNFa mRNA in lesional skin has led to
various post-translational TNF-activating mechanisms to
account for the increases in protein (Kawaguchi et al.,
2005; Johansen et al., 2006). We also did not observe
increased TNFa mRNA in lesional skin biopsies (Table 3) but
our tape-stripping data clearly show a significant increase in
TNFa mRNA.
As we see significant increases in TNFa mRNA in 90 of 95
lesion tape-strip samples (Table 2) there is little doubt that
tape stripping is recovering cells with increased TNFa mRNA
transcription. We hypothesize that these cells are in the very
upper aspect of lesions and in a biopsy sample contribute
little to the overall mRNA pool. Similar observations have
been reported by Wong et al. (2004) for IL-8 mRNA
expression in tape versus biopsy samples of normal and
irritated skin.
The potential for tape samples to enrich for surface cells
compared to biopsy samples is created by the much larger
surface area of the tape relative to the 4 mm punch biopsy,
resulting in a many-fold advantage for tape (discussed in
Wong et al., 2004). We conclude that TNFa mRNA is
increased in lesional tissue, largely in the immature stratum
corneum. This result supports the idea that a thorough
analysis of tape-strip samples of lesions may reveal differen-
tially expressed mRNAs that are not detected in biopsy
samples, which, if true will lead to a reanalysis of the role
this modified barrier might have on the expression and
maintenance of disease.
Inspection of the (gene/b-actin) mRNA ratio (i.e. DCt
values; Table S1) for IFNg, IL-12B, IL-23A, and vascular
endothelial growth factor (VEGF) also reveals that the (gene/
actin) mRNA ratios for these genes are higher in tape-strip
samples than in epidermis or dermis samples. Thus, five of
the seven mRNA we have assayed in tape and biopsy samples
have higher expression in mRNA samples obtained by tape
strippings.
In contrast to our discussion above on increased mRNA
expression in tape samples relative to deeper biopsy samples,
K16 mRNA expression shows a different pattern. Tape-strip
samples of lesional skin shows a slight but significant increase
(2-fold; Table 1) relative to non-lesional skin. In contrast,
biopsy samples of lesions display a large increase in K16
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mRNA expression relative to non-lesional skin (both epider-
mal and dermal fractions; Table 3). If one compares the (K16/
b-actin) mRNA ratio in tape-strip RNA from non-lesional
samples to that same ratio in lesion epidermal- or dermal-
biopsy samples we observe that this ratio is approximately
equal (i.e. compare the DCt, K16 values; 1.46 (non-lesional
skin, tape) vs 2.35 (lesional skin epidermis) vs 2.49
(lesional skin, dermis); Table S1). These data indicate that
tape stripping recovers a cell population from non-lesional
skin that is actively transcribing K16 mRNA almost to the
extent of psoriatic tissue (we observe similar data in tape-
stripping skin from normal, healthy individuals (data not
shown)). In a psoriatic lesion, this active transcription extends
to the epidermis and dermis and is virtually equal (Table S1).
The modest change in K16 mRNA expression in lesions
revealed by tape stripping make K16 mRNA expression a
poor biomarker in a tape-stripping assay.
We have used our DCt data (Table S1) for samples
recovered by tape-stripping non-lesional skin to establish
average control values for each mRNA. By comparison of
these average control DCt values to individual lesion DCt
values we can determine if an individual lesion overexpresses
a specific mRNA without reference to that particular patient’s
control skin. The result has been the demonstration that
some lesions have mRNA levels characteristic of
‘‘average’’ non-lesional skin. Thus, while the average
psoriatic lesion has increased quantities of the mRNAs shown
in Table 1, only 54% of the lesions had elevated levels of all
TNFa, IFNg, CD2, IL-12B, IL-23A, and VEGF mRNAs, the
remaining 46% of lesions had at least one mRNA within
control skin limits (K16 expression is not considered in this
analysis).
Intriguing in this analysis were six patients whose lesions
had normal levels of at least four of TNFa, IFNg, CD2, IL-12B,
IL-23A, and VEGF mRNAs. All six of these patients had
control levels of IL-23A and IL-12B, while five of six had
control levels of IFNg and CD2 mRNAs. Four of the six
patients had control levels of TNFa mRNA. In these six
patients, the remaining mRNAs which were not within
control values, were very close to that limit, suggesting that
the molecular physiology of these lesions was quite different
than that of the typical psoriatic lesion.
While the significance of these observations remains to be
elucidated it harmonizes with the widely held belief that the
disease waxes and wanes. Thus, it would be reasonable to
conjecture that quantitation of markers of disease activity of
lesional and non-lesional skin would have expression levels
that overlap. Over 20 years ago Krueger et al. noted that
while lesions of psoriasis have increased rates (2.3 times) of
epidermal proliferation, about 10% of subjects had average
proliferation rates from five lesional and five non-lesional
sites from similar anatomical locations that were nearly
identical (Krueger, 1981). Our findings of a cohort of lesions
where molecular markers of disease are similar to those seen
in non-lesional skin support a molecular basis for the waxing
and waning that seems inherent to this disease. The analyses
of message in this study further reinforce this early work and
Table 2 quantifies this concept.
The demonstration of heterogeneity in lesion mRNA
expression has precedent in the literature. Oestreicher et al.
(2001) analyzed lesions from eight patients by DNA
microarray and showed a wide variation in the patient-to-
patient values of differentially expressed genes compared to
control skin. Trepicchio et al. (1999) have suggested that
heterogeneity in K16 and IL-8 expression is correlated with
response or lack of response to human recombinant IL-11
therapy. In their study of IL-23 p19 and p40 subunit mRNA
expression, Lee et al. (2004) show individual patient data
revealing that some lesion mRNA expression is close to the
average non-lesional mRNA expression level.
The data in Table 2 invokes some provocative questions.
For instance, of the five patients with control values of lesion
TNFa mRNA levels, would an immunomodulatory agent
designed to decrease TNFa levels have a therapeutic effect?
Likewise, would the 24% of patients with control values of
CD2 mRNA in lesions respond to a therapy targeting CD2
protein? The answers to such questions have implications for
the potential efficacy of a therapeutic regime. Answering
these questions is beyond the scope of this report; however,
tracking RNA profiles via tape strips during clinical trials and
correlating them with clinical outcome would answer the
question as well as and do so without the downsides of
invasive biopsies.
We have recently shown that the method can be used to
sample patients undergoing treatment and we have observed
gene expression changes in lesions before clinical effect
(N. Benson, G. Krueger, unpublished observations). In
conclusion, our work demonstrates the utility of non-invasive
tape stripping as a means of collecting RNA from lesional and
non-lesional skin of psoriatic subjects. The nature of the
method allows it to be used repeatedly at the same site over
time or on many sites during a single visit, a quality that is
unique to this approach. We demonstrate that it is feasible to
sample psoriatic plaques and obtain valuable molecular data
with minimal discomfort to the patient, although clearly tape
stripping cannot provide samples of cells from the deep
epidermis or dermis. In addition, we have shown that tape
harvesting has identified a source of TNFa mRNA not
revealed by biopsy, suggesting that other markers of the
disease may have gone unnoticed in biopsies, thus demons-
trating that tape stripping could be a valuable supplement to
biopsy. This method may also be of value in non-life-
threatening diseases where a biopsy would not be an option
for a routine diagnostic test.
MATERIALS AND METHODS
Clinical protocol
This study was IRB approved and all patients signed informed
consent. The study was conducted according to the Declaration of
Helsinki Principles. Research subjects participating in tape stripping
were taken from a population of subjects enrolled in the Utah
Psoriasis Initiative (UPI, Salt Lake City, UT). During the initial UPI
examination, psoriasis severity was established using the National
Psoriasis Foundation Psoriasis Score (Carlin et al., 2003) for the
evaluation of erythema, induration, and scale, while a body surface
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area measurement was determined using the estimation of one
palm’s area of affected skin representing one percent body surface
area involvement.
Following the medical history and physical examination, those
subjects who showed an National Psoriasis Foundation Psoriasis
Score plaque induration of X3 (E0.75 mm) underwent tape
stripping of lesional and non-lesional sites. The choice of an
induration (thickness of plaque) scoreX3 was based on a frequency
analysis of induration of a large (B200) group of untreated subjects
using the National Psoriasis Foundation Psoriasis Score Card. This
card is embossed with six levels of elevation which increase at
0.25 mm intervals where a score of 0 is no elevation and a score of 5
corresponds to an elevation of X1.25 mm. This simple device was
developed to provide a consistent comparison of the induration of
lesions. The frequency analysis (unpublished data) showed that this
assessment of induration has a Gaussian distribution where thickness
scores of 3 were observed most frequently and where 1 and 5 were
observed least commonly. The psoriatic plaque chosen for tape
stripping was one that the investigator felt was representative of the
subject’s overall level of severity. Tape strips were handled with
gloves so as not to contaminate the samples with the investigator’s
RNA. A circular tape disc was placed on the lesion and, using the
rounded end of a pen, Eppendorf tube or the investigator’s thumb,
moderate to hard pressure was applied to the disc and moved in a
circular fashion to cover the surface of the tape for 20 cycles or for
approximately 20 seconds. The tape disc was then removed and
placed into its storage bag. This process was repeated at precisely the
same site with an additional three tape discs. Collection of non-
lesional skin took place in a similar manner, with four discs applied
sequentially to each of three non-lesional sites. Thus, each subject
had a total of 12 tape discs collected from non-lesional sites and four
tape discs from lesional skin. The three sites used for the collection of
non-lesional skin were: the deltoid and sites bilaterally on the back
at the level of the mid trapezius; as the project proceeded the
mastoid process was substituted for deltoid sites. If these areas had
nearby disease, defined as o5cm from the proposed site, clinically
normal skin from other, non-extensor sites above the elbow and knee
were used as the non-lesional site; intertriginous, facial, scalp, and
genital skin sites were not used. Immediately after placing the tape discs
into their storage bags the samples were moved to a freezer and stored at
701C. At the time of transport, the samples were placed in dry ice and
delivered overnight to DermTech International for RNA isolation.
The biopsy sites for the 10 subjects donating both tape strips and
biopsies were from the same general locations as the tape strips.
Biopsy and tape-strip sites were within 2 cm of each other for both
the lesional and non-lesional skin. Local anesthesia, 1% xylocaine,
was used for each of the 4 mm punch biopsies collected. Biopsies
were immediately placed in RNA Later at 41C. After 96 hours the
upper layer (which our experience shows contains most to all of the
epidermis) was manually sliced away from the remainder (mostly
dermis) of the biopsy with a thin double-edged razor blade while
holding the dermal component with a forceps. The thickness of the
biopsy was measured with a micrometer that accurately measures to
1mm; the upper, mostly epidermal component, of non-lesional
biopsies ranged in thickness from 100 to 120mm and that of lesional
skin ranged from 110 to 150 mm. Storage in RNA Later partially fixes
the skin which makes it easier to identify the boundary of the
epidermis and dermis and the firmness facilitates the manual
separation of epidermis from the dermis. Each component was
returned to clean RNA Later, and stored at 701C until shipped on
dry ice to DermTech International. Care was taken, throughout the
process – from taking the biopsy to separation of the skin into the two
layers – to avoid contaminating the specimens with RNA from the
operator by using gloves, clean slides, and instruments that had
been placed in a flame until red hot. Data for only nine psoriatic lesion
biopsies are presented because one sample was lost during handling.
Materials and reagents
The tape used was purchased from Adhesives Research (PN 90068-
991; Glen Rock, PA) in bulk rolls. These rolls were custom fabricated
into small circular discs, 17 mm in diameter, by Diagnostic
Laminations Engineering (Oceanside, CA). The adhesive on this
tape is a synthetic rubber and was chosen because it seems to
recover more RNA from normal skin than acrylic-based tapes (data
not shown). In comparison of this tape to D-squame (CuDerm,
Dallas, TX) and several acrylic adhesives provided by Adhesives
Research we found that the 90068 adhesive outperformed acrylic
adhesives for the amount of RNA recovered with four tapes applied
to a site on the upper back (data not shown). In addition, we found
that the 90068 adhesive mounted on a polyurethane (soft and
flexible) backing outperformed the same adhesive on a polyester
(rigid) backing (data not shown). However, it is likely that less-
efficient tapes will recover RNA, but will require higher numbers of
tape applications to do so. Total spleen RNA was purchased from
Ambion (Austin, TX). RNeasy RNA extraction kit and Sensiscript
Reverse Transcriptase kit were purchased from Qiagen (Valencia,
CA). PCR primers and probes (TaqMan Pre-Developed Assay
Reagents) and TaqMan Universal Master Mix, which included all
buffers and enzymes necessary for the amplification and fluorescent
detection of specific cDNAs, were purchased from Applied
Biosystems (Foster City, CA).
Isolation of RNA
The RNA within skin cells adherent to the four tapes used to harvest
a site was pooled by simultaneously extracting the tapes in a volume
of buffer RLT as previously described (Wong et al., 2004). In addition
to this procedure, we have recently developed an alternative
protocol that speeds processing considerably; this is our current
preferred method. This procedure uses a novel pressure cycling
technology to lyse skin cells (Garrett et al., 2002; Schumacher et al.,
2002). Tapes are extracted in pairs by insertion into a PULSETM tube
(Pressure Biosciences, Gaithersburg, MD) with 1.2 ml of buffer RLT
(supplied in the Qiagen RNeasy kit). The buffer used to extract the
first two tapes in a set of four was used to extract the second pair of
tapes in order to pool the contents of all four tapes. The PULSETM tube
is inserted into the pressure cycling technology-NEP2017 pressure
cycler and the sample is pressure extracted using the following
parameters: room temperature, five pressure cycles of 35 Kpsi with
pressure held for 20 seconds at the top and bottom of each cycle.
After pressure extraction the buffer is removed and processed
according to the standard Qiagen RNeasy protocol. For control
samples, which involved pooling three sites (12 tapes), each set of
four tapes was extracted and treated separately until the column
purification stage, at which point all three control samples were
adsorbed onto the same column. We have found that purification
protocols which dissolve the adhesive (e.g., phenol/chloroform)
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interfere with the recovery of RNA with Qiagen column purification
kits, this was true even when purified RNA was spiked onto a fresh
tape before phenol extraction (data not shown). For biopsy samples,
epidermal and dermal fractions (described above) were extracted
using the pressure cycling technology procedure in 1.2 ml of buffer
RLT and RNA purified with the RNeasy kit.
Reverse transcription and amplification/detection
Of RNA, 10ml was reverse transcribed into cDNA with the Sensiscript
Reverse Transcriptase kit using random hexamer primers in a final volume
of 20ml according to the manufacturer’s directions. The reaction was
diluted 5-fold with sterile, nuclease-free water for use in the subsequent
amplification/detection reaction. For each specific mRNA detection, three
replicate RTþ reactions and one RT (no reverse transcriptase; negative
control) reaction were performed. Two amplification/detection reactions
were carried out on each RTþ reaction to yield a total of six independent
determinations of the threshold value (Ct; discussed below). Amplification
and detection assays were performed using TaqMan Pre-Developed
Assay Reagents (b-actin, 4326315E; TNFa, Hs99999043_m1; IFNg,
Hs99999041_m1; Keratin 16, Hs00373910_g1; CD2, Hs00233515_m1;
IL-12B (p40), Hs00233688_m1; IL-23A (p19), Hs00372324_m1; VEGF,
Hs00173626_m1; Applied Biosystems, Foster City, CA) or Assay on
Demand reagents on an Applied Biosystems 7900HT Sequence Detection
System as previously described (Wong et al., 2004). All RT reactions
were amplified using two replicates and were negative (data not
shown).
Quantitation of RNA and determination of fold change
Quantitation of RNA mass was performed as previously described
(Wong et al., 2004). Briefly, RNA mass recovered from tapes is
determined by using quantitative reverse transcriptase-PCR with
reference to a standard curve (Ct,actin vs log[RNA]; AppliedBiosys-
tems 2001) created from commercially purchased human spleen
total RNA. Amplification and detection of unknowns was accom-
plished using b-actin mRNA as the quantified marker. The average of
six replicate Ct,actin values was used to calculate the concentration of
RNA in a sample with reference to the standard curve. The
calculation of change in gene expression was determined using
the comparative or DDCt method as described by Wong et al. (2004).
In this method (50-nuclease assay, ‘‘real-time’’ PCR) experimental
data is reported as the number of PCR cycles required to achieve a
threshold fluorescence (the ‘‘Ct’’ value; Gibson et al., 1996; Heid
et al., 1996; AppliedBiosystems 2001). Each reported Ct is the mean
of six replicate assays (described above) and is directly related to the
starting concentration of specific cDNA in the sample. In order to
compensate for samples with different total RNA masses, individual
mRNAs are normalized to b-actin mRNA in each sample. Normal-
ization is accomplished by separate assay of b-actin mRNA and
subsequent determination of the DCt,gene value which is equal to
Ct,geneCt,actin. The DCt value is a measure of specific mRNA relative
to b-actin mRNA in a sample (Z) and is related to the (gene/b-actin)
mRNA ratio by the equation:
mRNAX
mRNAbactin
 
SampleZ
¼ k2DCt;X ¼ k2ðCt;XCt;actinÞ
In practice, ‘‘k’’ is an unknown constant related to the PCR
conditions and the fluorescent probe; because k is unknown, the
absolute ratio in a sample is also unknown; therefore, in order to
determine changes in gene expression using this method, experi-
mental samples must be calibrated to a control sample, which in this
work is typically from uninvolved skin. Thus, given two samples
(psoriatic lesion and control skin), the change in the (TNFa/b-actin)
mRNA ratio in the lesion relative to the control is given by the
equation below:
mRNATNF
mRNAactin
 
lesion

mRNATNF
mRNAactin
 
control
¼ 2DDC lesiont;TNF :
Where DDC lesiont;TNF ¼ DC lesiont;TNF  DCcontrolt;control and DCt is defined above. All
normalized gene expression values (DCt values) were calculated
from Ct values of the gene of interest and b-actin, which were
determined during the same amplification/detection assay. In this
work, we typically refer to changes in the (gene/actin) mRNA ratio
relative to a control ratio to infer a change in the mRNA of interest;
occasionally refer to changes in specific gene expression, however,
it is to be understood that all changes in gene expression are inferred
by reference to the (gene/actin) mRNA ratio and the assumption that
b-actin expression is unchanged between the experimental and
control samples, this assumption was verified for sodium lauryl
sulfate-irritated skin (Wong et al., 2004) and we believe accurate for
psoriatic skin (N. Benson, unpublished observations).
Classification of psoriatic and control mRNA expression levels
Statistical analysis of average DCt data in Table S1 demonstrates that
these values are significantly different for lesional and control skin.
To determine if a particular DCt value is more characteristic of
lesional or control skin we assign it to one or the other category if the
DCt is within 1 SEM of either the average lesion DCt or control DCt.
We have used this strategy to define whether lesion DCt values are
within non-lesional limits (Table 2). To classify a lesion DCt value as
within non-lesional limits we have taken the average non-lesional
DCt value for a specific mRNA and added one SEM. If a lesion
sample has a DCt greater than or equal to this value, that DCt (hence
that lesion) is classified as within control limits.
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